RBC Capital analyst Gregory Renza downgraded Morphic (MORF) to Sector Perform from Outperform with a price target of $57, down from $70. The firm views the Eli Lilly (LLY) takeover price as “fair and solid.” With limited antitrust concerns, RBC expects the deal to close in Q3 as guided.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: